Cargando…

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment

SIMPLE SUMMARY: Pimavanserin a novel anti-psychotic drug suppresses the growth of pancreatic tumors in vitro and in vivo and can be developed as a treatment option for pancreatic cancer. ABSTRACT: Pancreatic tumors exhibit high basal autophagy compared to that of other cancers. Several studies inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramachandran, Sharavan, Kaushik, Itishree S., Srivastava, Sanjay K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616166/ https://www.ncbi.nlm.nih.gov/pubmed/34830816 http://dx.doi.org/10.3390/cancers13225661

Ejemplares similares

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Role of Phytochemicals in Cancer Prevention
por: Ranjan, Alok, et al.
Publicado: (2019)

Pimozide Suppresses the Growth of Brain Tumors by Targeting STAT3-Mediated Autophagy
por: Ranjan, Alok, et al.
Publicado: (2020)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats
por: Tripathi, Ashutosh, et al.
Publicado: (2023)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

The protective effects of Pimavanserin against cerebral ischemia-induced brain injury
por: Li, Xiang, et al.
Publicado: (2021)

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
por: Livezey, Sabrina, et al.
Publicado: (2021)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date
por: Soogrim, Vicki, et al.
Publicado: (2021)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered
por: Bokser, Allan David, et al.
Publicado: (2022)

Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis
por: Ranjan, Alok, et al.
Publicado: (2016)

Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats
por: Price, Amanda E., et al.
Publicado: (2018)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020)

Pimavanserin Use in Lewy Body Dementia: A Case Report Demonstrating the Medication’s Efficacy
por: Baker, Michelle, et al.
Publicado: (2023)

Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells
por: Gupta, Nehal, et al.
Publicado: (2021)

Neuroleptic Sensitivity in Dementia with Lewy Body and Use of Pimavanserin in an Inpatient Setting: A Case Report
por: Abadir, Anthony, et al.
Publicado: (2022)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study
por: Darwish, Mona, et al.
Publicado: (2022)

Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study
por: Forman, Mark, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2j7mp3ofib28a21k07b4h28r1i